SARS-CoV-2核衣壳血浆抗原用于COVID-19诊断与监测
本研究采用超灵敏电化学发光免疫分析法检测104例COVID-19患者共777份血浆样本中的SARS-CoV-2核衣壳抗原。血浆抗原临床敏感性91.9%(95%CI 83.2%-97.0%),特异性94.2%(84.1%-98.8%)。调整年龄、性别、糖尿病和高血压后,诊断时血浆抗原浓度与ICU入住相关(OR 2.8,95%CI 1.2-6.2,P=.01),但与普通住院无关。
要点
- 血浆核衣壳抗原诊断COVID-19敏感性91.9%、特异性94.2%。
- 抗原阴性血浆多来自呼吸道Ct值较晚的患者。
- 血浆抗原浓度与ICU入住独立相关,可用于分诊。
核心结论
- SARS-CoV-2血浆核衣壳抗原诊断性能与上呼吸道NAAT相当,尤其在呼吸道Ct较晚者中。
- 诊断时血浆抗原浓度与ICU入住相关,可能辅助患者分诊以优化重症监护资源。
研究设计与样本
- 采用超灵敏电化学发光免疫分析法检测104例COVID-19患者的777份血浆样本。
- 在74例COVID-19患者中比较血浆抗原与诊断性呼吸道NAAT(采样在NAAT±1天内),并纳入52例SARS-CoV-2阴性个体。
- 使用Kruskal-Wallis检验、多变量logistic回归和混合效应模型评估血浆抗原浓度与疾病严重程度的关系。
主要发现
- 血浆抗原临床敏感性91.9%(95%CI 83.2%-97.0%),临床特异性94.2%(84.1%-98.8%)。
- 抗原阴性血浆样本对应的患者呼吸道Ct值较抗原阳性者更晚。
- 血浆抗原浓度中位数(log10 fg/mL):门诊患者5.4(IQR 3.9-6.0),住院患者6.0(5.4-6.5),ICU患者6.6(6.1-7.2)。
- 调整年龄、性别、糖尿病和高血压后,诊断时血浆抗原浓度与ICU入住相关(OR 2.8,95%CI 1.2-6.2,P=.01),与非ICU住院无关。
- 抗原下降速率与疾病严重程度无关。
关键数值与推荐
- 血浆抗原临床敏感性91.9%(95%CI 83.2%-97.0%),特异性94.2%(84.1%-98.8%)。
- 血浆抗原浓度中位数(log10 fg/mL):门诊5.4(IQR 3.9-6.0),住院6.0(5.4-6.5),ICU 6.6(6.1-7.2)。
- 诊断时血浆抗原浓度与ICU入住OR 2.8(95%CI 1.2-6.2),P=.01。
临床怎么用
- 血浆核衣壳抗原可作为COVID-19诊断的补充工具,尤其适用于呼吸道Ct较晚的患者。
- 诊断时血浆抗原浓度可辅助评估ICU入住风险,优化重症监护资源分配。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid antigen in blood has been described, but the diagnostic and prognostic role of antigenemia is not well understood. This study aimed to determine the frequency, duration, and concentration of nucleocapsid antigen in plasma and its association with coronavirus disease 2019 (COVID-19) severity. METHODS: We utilized an ultrasensitive electrochemiluminescence immunoassay targeting SARS-CoV-2 nucleocapsid antigen to evaluate 777 plasma samples from 104 individuals with COVID-19. We compared plasma antigen to respiratory nucleic acid amplification testing (NAAT) in 74 individuals with COVID-19 from samples collected ±1 day of diagnostic respiratory NAAT and in 52 SARS-CoV-2-negative individuals. We used Kruskal-Wallis tests, multivariable logistic regression, and mixed-effects modeling to evaluate whether plasma antigen concentration was associated with disease severity. RESULTS: Plasma antigen had 91.9% (95% CI 83.2%-97.0%) clinical sensitivity and 94.2% (84.1%-98.8%) clinical specificity. Antigen-negative plasma samples belonged to patients with later respiratory cycle thresholds (Ct) when compared with antigen-positive plasma samples. Median plasma antigen concentration (log10 fg/mL) was 5.4 (interquartile range 3.9-6.0) in outpatients, 6.0 (5.4-6.5) in inpatients, and 6.6 (6.1-7.2) in intensive care unit (ICU) patients. In models adjusted for age, sex, diabetes, and hypertension, plasma antigen concentration at diagnosis was associated with ICU admission [odds ratio 2.8 (95% CI 1.2-6.2), P=.01] but not with non-ICU hospitalization. Rate of antigen decrease was not associated with disease severity. CONCLUSIONS: SARS-CoV-2 plasma nucleocapsid antigen exhibited comparable diagnostic performance to upper respiratory NAAT, especially among those with late respiratory Ct. In addition to currently available tools, antigenemia may facilitate patient triage to optimize intensive care utilization.
引用
- Wang H, Hogan CA, Verghese M, et al. SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19. Clin Chem. 2021. PMID: 34605900. doi:10.1093/clinchem/hvab216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。